Clarification: "Roles of micro-RNA-29a in the Antifibrotic Effect of Farnesoid X Receptor on Hepatic Stellate Cells"

In the above article [Li J, Kuruba R, Gao X, Gandhi CR, Xi W and Li S (2011) *Mol Pharmacol* 80:191–200], the authors reported that FXR may play a role in the regulation of miR-29a gene in hepatic stellate cells. It should be noted that the putative FXRE that they identified is 1.9 kb downstream of miR-29a gene. It is likely that the cloned sequence serves as an enhancer rather than promoter, because it has been demonstrated that miR-29a is located in exon 4 of one uncharacterized gene [expressed sequence tag AI768447; Mott JL, Kurita S, Cazanave SC, Bronk SF, Werneburg NW, and Fernandez-Zapico ME (2010) Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-κB. *J Cell Biochem* 110:1155–1164] and shares the same promoter with this gene. The sequence that they identified is located downstream of miR-29a but in the intron area of that uncharacterized gene 9 (see figure below). Therefore, it is more appropriate to name the pGL3-miR-29a construct "miR-29a enhancer-luciferase reporter." These clarifications, however, do not change the authors' conclusion on a role of FXR in the regulation of miR-29a in hepatic stellate cells.

The authors apologize for any confusion or inconvenience this may have caused.

Downloaded from molpharm aspetjournals org at Universidade do Estado do Rio de Janeiro on December 1, 2012

